Log in to save to my catalogue

Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis

Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7109169

Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis

About this item

Full title

Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis

Publisher

Berlin/Heidelberg: Springer Berlin Heidelberg

Journal title

Journal of neurology, 2020-04, Vol.267 (4), p.1070-1079

Language

English

Formats

Publication information

Publisher

Berlin/Heidelberg: Springer Berlin Heidelberg

More information

Scope and Contents

Contents

Objective
To examine the impact on quality of life (QOL) of patients with hATTR amyloidosis with polyneuropathy treated with inotersen (Tegsedi™) versus placebo.
Methods
Data were from the NEURO-TTR trial (ClinicalTrials.gov Identifier: NCT01737398), a phase 3, multinational, randomized, double-blind, placebo-controlled study of inotersen...

Alternative Titles

Full title

Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7109169

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7109169

Other Identifiers

ISSN

0340-5354

E-ISSN

1432-1459

DOI

10.1007/s00415-019-09671-9

How to access this item